top
Search terms
Results 101 - 110 of 117 - ordered by :
Pages: 1 ... 6 7 8 9 10 11 12
Ehjcvp

In patients without left ventricular dysfunction and/or overt HF, three large studies (Heart Outcomes Prevention Evaluation, HOPE trial,3 the European trial on Reduction Of cardiac events with ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Stefania Paolillo, Pasquale Perrone Filardi

Date : 01/04/2015
Ehjcvp

Abstract Aims Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with increased risk of cardiovascular disease. Non-steroidal anti-inflammatory drugs (NSAIDs)Myocardial infarctionAtrial ...

European Heart Journal - Cardiovascular Pharmacotherapy, ORIGINAL ARTICLES, Anne-Marie Schjerning Olsen, Emil L. Fosbøl, Jannik Pallisgaard, Jesper Lindhardsen, Morten Lock Hansen, Lars Køber, ...

Date : 01/04/2015
Ehjcvp

[...]of progress made in HFREF therapy, cumulative mortality benefit amounts to almost a three-fold decrease in death rate whether in severe or in mild-to-moderate HFREF. In chronic HEFREF, it is ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Faiez Zannad

Date : 01/01/2015 Item size : 180641 bytes
Ehjcvp

The WG contributes to most ESC guidelines with expertise on cardiovascular pharmacotherapy. [...]over the last 2 years the WG has beenor is stillinvolved in eight ESC guidelines. Gender differences ...

European Heart Journal - Cardiovascular Pharmacotherapy, CORRESPONDENCE, Keld Kjeldsen

Date : 01/01/2015 Item size : 98083 bytes
Ehjcvp

Abstract Renal sympathetic denervation (RDN) has been proposed as a new treatment modality in patients with apparent treatment-resistant hypertension (TRH), a condition defined as persistent blood ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEW, Sverre E. Kjeldsen, Fadl Elmula M. Fadl Elmula, Ingrid Os, Alexandre Persu, Yu Jin, Jan A. Staessen

Date : 01/01/2015 Item size : 349851 bytes
Ehjcvp

[...]anti-GPIIb/IIIa agents are used in conditions such as acute coronary syndrome undergoing percutaneous intervention where the thrombotic tendency of human body become extremely high.1,2 Since the ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Shinichi Goto, Shinya Goto

Date : 01/01/2015 Item size : 149314 bytes
Ehjcvp

There are already several scientific journals within clinical cardiology; however, this new journal will have a specified focus on clinical cardiovascular pharmacology. Despite this fast development ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIALS, Stefan Agewall

Date : 01/01/2015 Item size : 98592 bytes
Ehjcvp

Thanks to these investigations, European and American scientific societies have developed guidelines that provide evidence-based recommendations for treating acute and chronic HF,1,2 including ...

European Heart Journal - Cardiovascular Pharmacotherapy, EDITORIAL, Francesco Pelliccia, Giuseppe M.C. Rosano

Date : 01/01/2015 Item size : 131344 bytes
Ehjcvp

Heart failureIron deficiencyIntroduction Heart failure (HF) is a common condition and one that is projected to increase significantly in the coming decades due to the ageing population and increased ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Sarah Fitzsimons, Robert Neil Doughty

Date : 01/01/2015
Ehjcvp

Proposed underlying mechanisms and heterogeneity in study endpoint definitions Various mechanisms have been described that may be responsible for the clinical presentation of angina pectoris in the ...

European Heart Journal - Cardiovascular Pharmacotherapy, REVIEWS, Peter Ong, Anastasios Athanasiadis, Udo Sechtem

Date : 01/01/2015